361 related articles for article (PubMed ID: 31673113)
1. The functional mechanisms of mutations in myelodysplastic syndrome.
Nagata Y; Maciejewski JP
Leukemia; 2019 Dec; 33(12):2779-2794. PubMed ID: 31673113
[TBL] [Abstract][Full Text] [Related]
2. Loss of 5q in myeloid malignancies - A gain in understanding of biological and clinical consequences.
Venugopal S; Mascarenhas J; Steensma DP
Blood Rev; 2021 Mar; 46():100735. PubMed ID: 32736878
[TBL] [Abstract][Full Text] [Related]
3. The molecular pathogenesis of the myelodysplastic syndromes.
Pellagatti A; Boultwood J
Eur J Haematol; 2015 Jul; 95(1):3-15. PubMed ID: 25645650
[TBL] [Abstract][Full Text] [Related]
4. Mutations of myelodysplastic syndromes (MDS): An update.
Ganguly BB; Kadam NN
Mutat Res Rev Mutat Res; 2016; 769():47-62. PubMed ID: 27543316
[TBL] [Abstract][Full Text] [Related]
5. SRSF2 Mutations Contribute to Myelodysplasia by Mutant-Specific Effects on Exon Recognition.
Kim E; Ilagan JO; Liang Y; Daubner GM; Lee SC; Ramakrishnan A; Li Y; Chung YR; Micol JB; Murphy ME; Cho H; Kim MK; Zebari AS; Aumann S; Park CY; Buonamici S; Smith PG; Deeg HJ; Lobry C; Aifantis I; Modis Y; Allain FH; Halene S; Bradley RK; Abdel-Wahab O
Cancer Cell; 2015 May; 27(5):617-30. PubMed ID: 25965569
[TBL] [Abstract][Full Text] [Related]
6. Genetic and epigenetic pathways in myelodysplastic syndromes: A brief overview.
Jhanwar SC
Adv Biol Regul; 2015 May; 58():28-37. PubMed ID: 25499150
[TBL] [Abstract][Full Text] [Related]
7. Genetic abnormalities and pathophysiology of MDS.
Hosono N
Int J Clin Oncol; 2019 Aug; 24(8):885-892. PubMed ID: 31093808
[TBL] [Abstract][Full Text] [Related]
8. [Ineffective erythropoiesis in myelodysplastic syndrome].
Iwama A
Rinsho Ketsueki; 2018; 59(6):793-797. PubMed ID: 29973461
[TBL] [Abstract][Full Text] [Related]
9. Recurrent genetic defects on chromosome 5q in myeloid neoplasms.
Hosono N; Makishima H; Mahfouz R; Przychodzen B; Yoshida K; Jerez A; LaFramboise T; Polprasert C; Clemente MJ; Shiraishi Y; Chiba K; Tanaka H; Miyano S; Sanada M; Cui E; Verma AK; McDevitt MA; List AF; Saunthararajah Y; Sekeres MA; Boultwood J; Ogawa S; Maciejewski JP
Oncotarget; 2017 Jan; 8(4):6483-6495. PubMed ID: 28031539
[TBL] [Abstract][Full Text] [Related]
10. The genetic and molecular pathogenesis of myelodysplastic syndromes.
Shallis RM; Ahmad R; Zeidan AM
Eur J Haematol; 2018 Sep; 101(3):260-271. PubMed ID: 29742289
[TBL] [Abstract][Full Text] [Related]
11. Spliceosome mutations exhibit specific associations with epigenetic modifiers and proto-oncogenes mutated in myelodysplastic syndrome.
Mian SA; Smith AE; Kulasekararaj AG; Kizilors A; Mohamedali AM; Lea NC; Mitsopoulos K; Ford K; Nasser E; Seidl T; Mufti GJ
Haematologica; 2013 Jul; 98(7):1058-66. PubMed ID: 23300180
[TBL] [Abstract][Full Text] [Related]
12. Mutation-Driven Therapy in MDS.
Swoboda DM; Sallman DA
Curr Hematol Malig Rep; 2019 Dec; 14(6):550-560. PubMed ID: 31760573
[TBL] [Abstract][Full Text] [Related]
13. The utility of a myeloid mutation panel for the diagnosis of myelodysplastic syndrome and myelodysplastic/myeloproliferative neoplasm.
Ibrar W; Zhang W; Cox JL; Cushman-Vokoun A; Fu K; Greiner TC; Yuan J
Int J Lab Hematol; 2021 Dec; 43(6):1501-1509. PubMed ID: 34270867
[TBL] [Abstract][Full Text] [Related]
14. Identification of Lenalidomide Sensitivity and Resistance Mechanisms in Non-Del(5q) Myelodysplastic Syndromes.
Drusbosky LM; Cogle CR
Int J Mol Sci; 2020 May; 21(9):. PubMed ID: 32397113
[TBL] [Abstract][Full Text] [Related]
15. Genome-wide miRNA profiling in myelodysplastic syndrome with del(5q) treated with lenalidomide.
Merkerova MD; Krejcik Z; Belickova M; Hrustincova A; Klema J; Stara E; Zemanova Z; Michalova K; Cermak J; Jonasova A
Eur J Haematol; 2015 Jul; 95(1):35-43. PubMed ID: 25287904
[TBL] [Abstract][Full Text] [Related]
16. Altered EZH2 splicing and expression is associated with impaired histone H3 lysine 27 tri-Methylation in myelodysplastic syndrome.
Shirahata-Adachi M; Iriyama C; Tomita A; Suzuki Y; Shimada K; Kiyoi H
Leuk Res; 2017 Dec; 63():90-97. PubMed ID: 29127861
[TBL] [Abstract][Full Text] [Related]
17. Distinct and convergent consequences of splice factor mutations in myelodysplastic syndromes.
Madan V; Li J; Zhou S; Teoh WW; Han L; Meggendorfer M; Malcovati L; Cazzola M; Ogawa S; Haferlach T; Yang H; Koeffler HP
Am J Hematol; 2020 Feb; 95(2):133-143. PubMed ID: 31680297
[TBL] [Abstract][Full Text] [Related]
18. Genetics of MDS.
Ogawa S
Blood; 2019 Mar; 133(10):1049-1059. PubMed ID: 30670442
[TBL] [Abstract][Full Text] [Related]
19. Impact of combinatorial dysfunctions of Tet2 and Ezh2 on the epigenome in the pathogenesis of myelodysplastic syndrome.
Hasegawa N; Oshima M; Sashida G; Matsui H; Koide S; Saraya A; Wang C; Muto T; Takane K; Kaneda A; Shimoda K; Nakaseko C; Yokote K; Iwama A
Leukemia; 2017 Apr; 31(4):861-871. PubMed ID: 27694924
[TBL] [Abstract][Full Text] [Related]
20. Somatic mutations and epigenetic abnormalities in myelodysplastic syndromes.
Itzykson R; Kosmider O; Fenaux P
Best Pract Res Clin Haematol; 2013 Dec; 26(4):355-64. PubMed ID: 24507812
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
